The miR-30 family: Versatile players in breast cancer

The microRNA family, miR-30, plays diverse roles in regulating key aspects of neoplastic transformation, metastasis, and clinical outcomes in different types of tumors. Accumulating evidence proves that miR-30 family is pivotal in the breast cancer development by controlling critical signaling pathw...

Full description

Saved in:
Bibliographic Details
Published in:Tumor Biology 2017-03, Vol.39 (3), p.1010428317692204
Main Authors: Yang, Su-Jin, Yang, Su-Yu, Wang, Dan-Dan, Chen, Xiu, Shen, Hong-Yu, Zhang, Xiao-Hui, Zhong, Shan-Liang, Tang, Jin-Hai, Zhao, Jian-Hua
Format: Article
Language:English
Subjects:
Apoptosis
Biomarkers
Biomarkers, Tumor - genetics
Biomarkers, Tumor - metabolism
Bladder cancer
Breast cancer
Breast Neoplasms - genetics
Breast Neoplasms - metabolism
Breast Neoplasms - pathology
Carcinogenesis - genetics
Carcinogenesis - metabolism
Cell growth
Colorectal cancer
Drug resistance
Drug Resistance, Neoplasm
Female
Gastric cancer
Genes
Humans
Leukemia
Liver cancer
Lung cancer
Medical prognosis
Metastases
Metastasis
MicroRNAs - genetics
MicroRNAs - metabolism
miRNA
Multiple myeloma
Neoplasm Metastasis
Physiology
Prostate
Proteins
Signal Transduction - genetics
Tumorigenesis
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The microRNA family, miR-30, plays diverse roles in regulating key aspects of neoplastic transformation, metastasis, and clinical outcomes in different types of tumors. Accumulating evidence proves that miR-30 family is pivotal in the breast cancer development by controlling critical signaling pathways and relevant oncogenes. Here, we review the roles of miR-30 family members in the tumorigenesis, metastasis, and drug resistance of breast cancer, and their application to predict the prognosis of breast cancer patients. We think miR-30 family members would be promising biomarkers for breast cancer and may bring a novel insight in molecular targeted therapy of breast cancer.
ISSN:1010-4283
1423-0380
DOI:10.1177/1010428317692204